Incumplimiento en terapia antineoplásica, factores pronóstico

• Autores: Pilar Llopis Salvià, A. Sánchez Castelló, Agustín Sánchez Alcaraz
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 7, Nº. 1, 2005, págs. 9-18
• Idioma: español
• Títulos paralelos:
  • Prognostic factors for non fulfillement antineoplasic treatment
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To determine the therapeutic unfulfillment in patients that receive antineoplastic chemotherapy and to identify their prognosis. Method: Retrospective observational study of patients that received 3 or more cycles of adjuvant or neo-adjuvant antineoplastic chemotherapy diagnosed with breast tumor and treated according to the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) scheme, colorectal cancer under treatment with Mayo Clinic's 5FU/LV scheme (5-fluorouracil, leucovorin), non-microcytic lung carcinoma under treatment with mitomycin, cisplatin and iphosphamide (MIP), ovarian carcinoma under treatment with paclitaxel and carboplatin (PC scheme) and neoplasia that affects both head and neck with AL-SARRAF scheme. Therapeutic unfulfillment is defined as an dose intensity rate (DIR) (expressed in percentage terms) lower than 90% of the initially planned for each patient. Results: The global unfulfillment of the sample under study, in terms of DIR, was of 33% for the 5FU-LV scheme, 54% for the CMF scheme, 57% for the MIP scheme, 77% for the PC scheme and 37% for the AL-SARRAF scheme. Conclusion: The type of chemotherapy received is the main factor that influence the degree of treatment unfulfillment, followed by age. Patients older than 65 years of age present a greater risk of receiving less DIR